Pharmacological adjuvants for surgical treatment of proliferative vitreoretinopathy;Adjuvants pharmacologiques du traitement chirurgical de la prolifération vitréorétinienne

Journal Francais d'Ophtalmologie

Volumn 27, Issue 9 I, 2004, Pages 1051-1059

  Scheer, S ^a   Morel, C ^a   Touzeau, O ^a   Sahel, J A ^a   Laroche, L ^a  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

Author keywords

13 cis retinoic acid; 5 fluorouradle; Adjuvants; Colchicine; Daunomycin; Heparin; Proliferative vitreoretinopathy; Retinal detachment; Silicone; Steroids

Indexed keywords

2' BENZOYLOXYCINNAMALDEHYDE; CINNAMALDEHYDE DERIVATIVE; COLCHICINE; CORTICOSTEROID; DAUNORUBICIN; DEXAMETHASONE; FLUOROURACIL; HEPARIN; HYDROXYPROLINE; ISOTRETINOIN; MITOMYCIN; SILICON; TRIAMCINOLONE; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ARTICLE; CATARACT; CLINICAL TRIAL; DRUG EFFICACY; GLAUCOMA; HUMAN; NONHUMAN; RETINA DETACHMENT; RISK FACTOR; SIDE EFFECT; SURGICAL TECHNIQUE; VITREORETINOPATHY;

EID: 9344240392     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0181-5512(04)96264-X     Document Type: Article

References (76)

1. Grierson I, Mazure A, Hogg P, Hiscott P, Sheridan C, Wong D. Non-vascular vitreoretinopathy: the cells and the cellular basis of contraction. Eye, 1996;10:671-84.
2. Michels R, Wilkinson C, Rice T. Retinal detachment. Second edition. Mosby New York, 1996.
3. Machemer R. Pathogenesis and classification of massive preretinal proliferation. Br J Ophthalmol, 1978;62:737-47.
4. The Retina Society Terminology Committee. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology, 1983;90:121-5.
5. Machemer R, Aaberg TM, Freeman HM, et al. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol, 1991;112:159-65.
6. Machemer R. Massive periretinal proliferation: a logical approach to therapy. Tr Am Ophth Soc, 1977;75:557-86.
7. Hiscott P, Sheridan C, Magee RM, Grierson I. Matrix and the retinal pigment epithelium in proliferative retinal disease. Prog Retin Eye Res, 1999;18:167-90.
8. Hooymans JM, Renardel de Lavalette VW, Oey AG. Formation of proliferative retinopathy in primary rhegmatogenous retinal detachment. Doc Ophthalmol, 2000;100:39-42.
9. Girard P, Mimoun G, Karpousas I, Montefiore G. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina, 1994;14:417-24.
10. Kon CH, Asaria RH, Occleston NL, et al. Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study. Br J Ophthalmol, 2000;84:506-11.
11. Kon CH, Occleston NL, Charteris D, et al. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci, 1998;39:1524-9.
12. Cousins SW, Rubsamen PE. Comparison of flow cytometry with the surgeon regarding ability to predict the ultimate success of surgery for proliferative vitreoretinopathy. Arch Ophthalmol, 1994;112:1554-60.
13. Briggs MC, Grierson I, Hiscott P, Hunt JA. Active Scatter Factor (HGF/SF) in proliferative vitreoretinal disease. Invest Ophthalmol Vis Sci, 2000;41:3085-94.
14. Mitamura Y, Takeuchi S, Matsuda A, et al. Hepatocyte growth factor levels in the vitreous of patients with proliferative vitreoretinopathy. Am J Ophthalmol, 2000;129:678-80.
15. Cassidy L, Barry P, Shaw C, Duffy J, Kennedy S. Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders. Br J Ophthalmol, 1998;82:181-5.
16. Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH. Soluble TNF Receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci, 2001;42:1586-91.
17. Kon CH, Occleston NL, Aylward GW, Khaw PT. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci, 1999;40:705-12.
18. Troger J, Kremser B, Stöckl T, et al. Elevated levels of calcitonine gene-related peptide in aqueous humor of patients with proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol, 2000;238:237-42.
19. Troger J, Kremser B, Irschick E, Göttinger W, Kieselbach G. Substance P in proliferative vitreoretinopathy: the significance of aqueous humor levels for evolution of the disease. Graefes Arch Clin Exp Ophthalmol, 1998;236:900-3.
20. Su CY, Chen MT, Wu WS, Wu WC. Concentration of vascular endothelial growth factor in the subretinal fluid of retinal detachment. J Ocular Pharmacology Therapeutic, 2000;16:463-9.
21. Hui YN, Liang HC, Cai YS, Kirchhof B, Heimann K. Corticosteroïds and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages. Graefes Arch Clin Exp Ophthalmol, 1993;231:109-14.
22. Khawly JA, Saloupis P, Hatchell DL, Machemer R. Daunorubicin treatment in a redefined experimental model of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol, 1991;229:464-7.
23. Wiedemann P, Kirmani M, Santana M, Sorgente N, Ryan SJ. Control of experimental massive periretinal proliferation by daunomycin: dose response relation. Graefes Arch Clin Exp Ophthalmol, 1983;220:233-5.
24. Kirmani M, Santana M, Sorgente N, Wiedemann P, Ryan SJ. Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy. Control by daunomycin. Retina, 1983;3:269-72.
25. Santana M, Wiedemann P, Kirmani M, et al. Daunomycin in the treatment of experimental proliferative vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit. Graefes Arch Clin Exp Ophthalmol, 1984;221:210-3.
26. Steinhorst UH, Hatchell DL, Chen EP, Machemer R. Ocular toxicity of daunomycin: effects of subdivised doses on the rabbit retina after vitreous gas compression. Graefes Arch Clin Exp Ophthalmol, 1993;231:591-4.
27. Wiedemann P, Hilgers RD, Bauer P, Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Am J Ophthalmol, 1998;126:550-9.
28. Kumar A, Nainiwal S, Choudhary I, Tewari HK, Verma LK. Role of Daunorubicin in inhibating proliferative vitreoretinopathy after retinal detachment surgery. Clin Experiment Ophthalmol, 2002;30:348-51.
29. Wiedemann P, Leinung C, Hilgers R, Heimann K. Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol, 1991;229:150-2.
30. Wiedemann P, Lemmen K, Schmiedl R, Heimann K. Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy. Am J Ophthalmol, 1987;104:10-4.
31. Wiedemann P, Evans PY, Wiedeman R, Meyer-Schwickerat R, Heimann K. A fluorescein angiaographic study on patients with proliferative vitreoretinopathy treated by vitrectomy and intraocular daunomycin. Int Ophthalmol, 1989;13:211-6.
32. Stern WH, Lewis GP, Erickson PA, et al. Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy. Am J Ophthalmol, 1983;96:33-42.
33. Stern WH, Guerin CJ, Erickson PA, et al. Ocular toxicity of fluorouracil after vitrectomy. Am J Ophthalmol, 1983;96:43-51.
34. Blumenkranz MS, Ophir AO, Claflin AJ, Hajek A. Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol, 1982;94:458-67.
35. Binder S, Riss B, Skorpik Ch, Kulnig W. Inhibition of experimental intraocular proliferation with intravitreal 5-fluorouracil. Graefes Arch Clin Exp Ophthalmol, 1983;221:126-9.
36. Blankenship GW. Evaluation of a single intravitreal injection of 5-fluorouracil in vitrectomy cases. Graefes Arch Clin Exp Ophthalmol, 1989;227:565-8.
37. Blumenkranz M, Hernandez E, Ophir A, Norton E. 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology, 1984;91:122-30.
38. Tano Y, Chandler DB, Brooks WM, Machemer R. Glucocoticosteroid inhibition of intraocular proliferation after injury. Am J Ophthalmol, 1980;91:184-9.
39. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol, 1980;90:810-6.
40. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferation with intravitreal corticosteroids. Am J Ophthalmol, 1980;89:131-6.
41. Rubsamen PE, Cousins SW. Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy. Retina, 1997;17:44-50.
42. McCuen BW, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol, 1981;91:785-8.
43. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc, 1979;77:171-80.
44. Kilvicim M, Peyman GA, El-Dessouky ES, et al. Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surg Lasers, 2000;31:474-8.
45. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of cristalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol, 2000;84:1064-7.
46. Koerner F, Merz A, Gloor B, Wagner E. Postoperative retinal fibrosis - a controlled clinical study of systemic steroid therapy. Graefes Arch Clin Exp Ophthalmol, 1982;219:268-71.
47. Sakamoto T, Miyazaki M, Hisatomi T, et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol, 2002;240:423-9.
48. Blumenkranz MS, Hartzer MK, Iverson D. An overview of potential application of heparin in vitreoretinal surgery. Retina, 1992;12:S71-4.
49. Chapman C, Iverson D, Hartzer M, Minelli E, Blumenkranz M. The effect of low molecular weight heparin on proliferative vitreoretinopathy induced in the rabbit eye. Invest Ophthalmol Vis Sci, 1992;33:818.
50. Johnson RN, Blankenship G. A prospective, randomized, clinical trial of heparin therapy for postoperative intraocular fibrin. Ophthalmology, 1988;95:312-7.
51. Johnson RN, Balyeat E, Stern WH. Heparin prophylaxis for intraocular fibrin. Ophthalmology, 1987;94:597-601.
52. Williams RG, Chang S, Comaratta MR, Simoni G. Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy? Graefes Arch Clin Exp Ophthalmol, 1996;234:496-503.
53. Asaria RH, Kon CH, Bunce C, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology, 2001;108:1179-83.
54. Allinson RW. Adjuvant 5-FU and heparin prevent PVR. Ophthalmology, 2002;109:829-30.
55. Lemor M, Yeo JH, Glaser BM. Oral colchicine for the treatment of experimental traction retinal detachment. Arch Ophthalmol, 1986;104:1226-9.
56. Berman DH, Gombos GM. Proliferative vitreoretinopathy: does oral low-dose colchicine have an inhibitory effect? A controlled study in humans. Ophthalmic Surg, 1989;20:268-72.
57. Campochiaro PA, Hackett SF, Conway BP. Retinoic acid promotes density dependent growth arrest in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci, 1991;32:65-72.
58. Verstraeten T, Hartzer M, Wilcox DK, Cheng M. Effects of vitamin A on retinal pigment epithelial cells in vitro. Invest Ophthalmol Vis Sci, 1992;33:2830-8.
59. Doyle JW, Dowgiert RK, Buzney SM. Factors modulating the effects of retinoids on cultured retinal pigment epithelial cell proliferation. Curr Eye Res, 1992;11:753-65.
60. Araiz JJ, Refojo MF, Arroyo MH, et al. Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci, 1993;34:522-30.
61. Fekrat S, De Juan E, Campochiaro PA. The effect of oral 13-cis-retinoic acid on retinal detachment after surgical repair in eyes with proliferative vitreoretinopathy. Ophthalmology, 1995;102:412-8.
62. The Silicone Study Group. Vitrectomy with silicone oil or sulfur hexafloride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Arch Ophthalmol, 1992;110:770-9.
63. The Silicone Study Group. Vitrectomy with silicone oil or perflouropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Arch Ophthalmol, 1992;110:780-92.
64. Grey RHB, Leaver PK. Silicone oil in the treatment of massive preretinal retraction. I. Results in 105 eyes. Br J Ophthalmol, 1979;63:355-60.
65. Leaver PK, Grey RHB, Garner A. Silicone oil in the treatment of massive preretinal retraction. II. Late complications in 93 eyes. Br J Ophthalmol, 1979;63:361-7.
66. Arroyo MH, Refojo MF, Araiz JJ, et al. Silicone oil as a delivery vehicle for BCNU in rabbit proliferative vitreoretinopathy. Retina, 1993;13:245-50.
67. Van Bockxmeer FM, Martin CE, Thompson DE, Constable IJ. Taxol for the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci, 1985;26:1140-7.
68. Sunalp MA, Wiedemann P, Sorgente N, Ryan SJ. Effect of adriamycin on experimental proliferative vitreoretinopathy in the rabbit. Exp Eye Res 1985;41:105-15.
69. Ozerdem U, Mach-Hofacre B, Cheng L, et al. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy. Curr Eye Res, 2000;20:447-53.
70. Yu HG, Chung H. Antiproliferative effect of Mitomycin C on experimental proliferative vitreoretinopathy in rabbits. Korean J Ophthalmol, 1997;11:98-105.
71. Moritera T, Ogura Y, Yoshimura N, et al. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci, 1992;33:3125-30.
72. Murray TG, Stern WH, Chin DH, MacGowan-Smith EA. Collagen shield heparin delivery for prevention of postoperative fibrin. Arch Ophthalmol, 1990;108:104-6.
73. Joondeph BC, Peyman GA, Khoobehi B, Yue BY. Liposome-encapsulated 5-fluorouradl in the treatment of proliferative vitreoretinopathy. Ophthalmic Surg, 1988;19:252-6.
74. Ozerdem U, Mach-Hofacre B, Keefe K, et al. The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy. Ophthalmic Res, 2001;33:20-3.
75. Lee JJ, Park JK, Kim YT, et al. Effect of 2′-benzoyl- oxycinnamaldehyde on RPE cells in vitro and in an experimental proliferative vitreoretinopathy model. Invest Ophthalmol Vis Sci, 2002;43:3117-24.
76. Yasukawa T, Kimura H, Tabata Y et al. Sustained release of cis-hydroxyproline in the treatment of experimental proliferative vitreoretinopathy in rabbits. Graefes Arch Clin Exp Ophthalmol, 2002;240:672-8.